Overview

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Primary objective: To describe and compare the safety and efficacy of treatment with AAT in chronic pancreatitis patients who undergo total pancreatectomy and islet autotransplantation (TP-IAT).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Treatments:
Alpha 1-Antitrypsin
Protein C Inhibitor